Hypertension:需要警惕,高密度脂蛋白胆固醇也不是越高越好!

2022-08-23 MedSci原创 MedSci原创

该研究的数据表明高密度脂蛋白胆固醇水平与男性高血压患者心血管事件风险之间存在U型关联。

多年来,高密度脂蛋白胆固醇(HDL-C)被认为与心血管风险之间呈负相关性,这一假设主要基于流行病学研究的结果。它们表明HDL-C每增加1mg/dL,心血管死亡风险就会降低约2%至3%。然而,最新的流行病学和遗传学调查结果表明,HDL-C水平可能不能预测所有受试者的心血管预后。

最近,在无心血管疾病人群中进行的研究发现非常高的HDL-C水平可能与死亡风险增加有关。然而,HDL-C水平与特定心血管事件之间的确切关系仍然未知,尤其是在高血压患者等高危人群中。

为了进一步澄清这个问题,近日,心血管权威杂志Hypertension上发表了一篇研究文章,研究人员在意大利南部Campania Salute网络中分析了高血压患者HDL-C水平与心血管事件之间的关系。

该研究的工作人员分析了11987名高血压患者,并对他们进行了25534人次每年的随访。根据血浆HDL-C水平将参与者分为3组:HDL-C<40mg/dL(低HDL-C组);HDL-C在40-80mg/dL之间(中等HDL-C组);HDL-C>80mg/dL(高HDL-C组)。在后续分析中,调整了潜在的混杂因素,研究人员观察到与中等HDL-C组相比,低HDL-C组和高HDL-C组共发生245起心血管事件,心血管事件的风险也显著升高。样条分析显示HDL-C水平与心血管预后之间存在非线性U型关联。有趣的是,与高HDL-C相关的心血管风险增加并没有在女性患者中得到证实。

由此可见,该研究的数据表明高密度脂蛋白胆固醇水平与男性高血压患者心血管事件风险之间存在U型关联。

原始出处:

Valentina Trimarco.et al.High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients.Hypertension.2022.https://www.ahajournals.org/doi/epdf/10.1161/HYPERTENSIONAHA.122.19912

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039330, encodeId=9e962039330fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 08 09:39:36 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729750, encodeId=66d91e2975004, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Dec 13 18:39:36 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424846, encodeId=14ac142484691, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462996, encodeId=2ece146299604, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501593, encodeId=33061501593d8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039330, encodeId=9e962039330fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 08 09:39:36 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729750, encodeId=66d91e2975004, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Dec 13 18:39:36 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424846, encodeId=14ac142484691, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462996, encodeId=2ece146299604, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501593, encodeId=33061501593d8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=)]
    2022-12-13 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039330, encodeId=9e962039330fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 08 09:39:36 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729750, encodeId=66d91e2975004, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Dec 13 18:39:36 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424846, encodeId=14ac142484691, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462996, encodeId=2ece146299604, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501593, encodeId=33061501593d8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039330, encodeId=9e962039330fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 08 09:39:36 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729750, encodeId=66d91e2975004, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Dec 13 18:39:36 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424846, encodeId=14ac142484691, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462996, encodeId=2ece146299604, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501593, encodeId=33061501593d8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2039330, encodeId=9e962039330fd, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 08 09:39:36 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729750, encodeId=66d91e2975004, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Dec 13 18:39:36 CST 2022, time=2022-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424846, encodeId=14ac142484691, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462996, encodeId=2ece146299604, content=<a href='/topic/show?id=53ad1023343a' target=_blank style='color:#2F92EE;'>#高密度脂蛋白胆固醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102334, encryptionId=53ad1023343a, topicName=高密度脂蛋白胆固醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0236523207, createdName=zchen, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501593, encodeId=33061501593d8, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed Aug 24 14:39:36 CST 2022, time=2022-08-24, status=1, ipAttribution=)]

相关资讯

JAHA:白蛋白尿作为急性心肌梗死患者心血管预后的预测因子

由此可见,在MI患者中,白蛋白尿是后续结局的有效预测因子,这表明在这一高危人群中,除了肾功能外,还要注意患者白蛋白尿的信息。

JAHA:2型糖尿病患者代谢性血脂异常与心血管预后之间的关系

在超重/肥胖的2型糖尿病患者中,代谢性血脂异常与更高的心血管疾病结局风险相关。该研究的结果强调了在2型糖尿病患者的心血管疾病风险分层中考虑代谢性血脂异常的必要性。

JAMA Netw Open:减肥手术与心血管预后的关联

减肥手术与体重减轻、心血管危险因素的改善以及血管内皮表型的改善有关。

JAHA:肝脏纤维化评分作为预测择期PCI患者心血管预后的新工具

高LFSs可能有助于预测稳定型冠状动脉疾病患者PCI术后的不良预后,提示LFSs具有用于择期PCI术前风险分层中的可能性。

JAHA:动脉硬化的尿蛋白组谱与死亡率和心血管预后相关

PWV‐UP与PWV高度相关,可作为动脉硬化的生物标志物。PWV‐UP(而非PWV)与全因死亡率和心血管死亡率相关,这意味着PWV‐UP相关肽可能在多个方面参与了动脉硬化以外的多种病理过程。

JACC:西班牙研究,营养不良提示心梗患者预后差!

西班牙学者发表在JACC上的一项研究提示,在急性冠脉综合征患者中,营养不良很常见,而营养不良显著增加死亡和主要不良心血管事件发生风险。